Addressing Racial Disparities in Health Care

Latest News

What COVID-19 May Have Changed Forever About Multiple Myeloma Care — Telemedicine

COVID made oncologists rethink how to deliver care to their multiple myeloma patients, who are already at higher risk for infection. Providers increasingly shifted to telemedicine, and quickly realized its long-term benefits -- particularly for patients living far from major cancer centers.

Learn More

Selinexor Combo Effective For Relapsed Multiple Myeloma; Could it Benefit COVID Patients, Too?

Most multiple myeloma patients eventually relapse and their cancers become unresponsive to therapy, leaving them with limited remaining options and a poor prognosis. For these patients, the combination of selinexor plus dexamethasone represents a "critical new direction" in treatment.

Learn More

Could Ibrutinib Combined With Other Targeted Therapies and Chemo Be ‘the Future’ of B-Cell Lymphoma Treatment?

New research is enhancing our understanding of ibrutinib -- a Bruton's tyrosine kinase (BTK) inhibitor used to treat several different types of lymphoma, including chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and mantle cell lymphoma. It has also produced positive responses in B-cell lymphoma, but is so far only used in patients with relapsed/refractory disease.

Learn More

Brentuximab Vedotin is ‘Great Stride’ Toward Improving Lymphoma Outcomes

Brentuximab vedotin has added considerably to the lymphoma treatment options available to oncologists. The drug was initially approved for the treatment of relapsed Hodgkin's lymphoma following a stem cell transplant or, in patients who could not have a transplant, for those who had already undergone two or more chemotherapy treatments.

Learn More

Bispecific Antibodies Offer Lymphoma Patients a Promising New Therapeutic Option

Bispecific antibodies have exciting potential as a cancer therapy, due to their ability to simultaneously bind to two targets. Right now, this treatment is only available in investigational trials, but it has shown promising outcomes for patients with relapsed-refractory lymphoma who have already undergone a transplant, CAR T-cell therapy, or other lines of treatment.

Learn More

Overcoming Racial Disparities in Multiple Myeloma Research and Care

Multiple myeloma has one of the most dramatic racial disparities of any cancers. Black Americans are more than twice as likely to get this cancer than white Americans. They're also more likely to die from multiple myeloma.

Learn More

The Clinical Trial Disparity: Why So Few Black Patients Enroll

In trials for 24 of the 31 cancer drugs approved since 2015, fewer than 5% of participants were Black. As a result of this disparity, Black patients aren't getting access to experimental, and possibly lifesaving new therapies.

Learn More

How to Prevent COVID-19 From Taking a Toll on Your Mental Health

We often talk about COVID-19 in terms of infections and deaths. What sometimes remains unspoken is the emotional toll this virus has had, not only on patients, but also on the doctors, nurses, and other health professionals who care for them. Research finds that these frontline medical workers face high levels of depression, anxiety, and stress.

Learn More